Skip to main content

Table 2 Ventilator parameters and patient characteristics during the study protocol

From: Neurally adjusted ventilatory assist vs. pressure support to deliver protective mechanical ventilation in patients with acute respiratory distress syndrome: a randomized crossover trial

ID MVdays Mode PS Cycloff NAVAL PEEP FIO2 P/F Sedation RASS
1 6 PCV 13 30% 2.4 11 0.45 151 F − 5
2 7 PCV NA NA NA 16 0.35 183 None − 2
3 3 PCV NA NA NA 14 0.60 129 F, P − 4
4 3 PCV 5 30% 0.2 15 0.30 376 F, P − 4
5 1 PCV 8 25% 1.2 10 0.50 296 None 0
6 3 PCV 10 30% 0.6 10 0.45 136 F − 4
7 4 PCV 6 40% 1.4 8 0.40 265 F, P − 4
8 3 VCV 6 35% 0.4 8 0.30 281 F, M − 5
9 3 PCV NA NA NA 8 0.50 114 F, M, D + 1
10 2 PCV 5 30% 0.8 15 0.50 187 F, P − 4
11 3 PCV NA NA NA 8 0.30 213 P − 3
12 3 VCV 5 30% 0.6 10 0.30 240 F − 2
13 3 PCV 7 30% 0.3 10 0.35 193 F, M − 4
14 3 PCV 6 30% 0.5 10 0.30 280 D − 1
15 2 VCV 8 30% 2.0 10 0.50 137 F, P, M − 3
16 4 PCV 12 15% 2.2 10 0.45 170 None − 3
17 2 VCV 7 30% 0.5 8 0.40 215 F, M − 4
18 4 VCV 10 30% 0.8 12 1.00 133 F 0
19 5 PCV NA NA NA 13 1.00 314 F, P − 4
20 4 VCV NA NA NA 10 0.45 149 F, M − 3
  1. ID patient identification, MVdays days of mechanical ventilation before inclusion on the study, PS pressure support, Cycloff cycling off in pressure support mode, NAVAL level of neurally adjusted ventilatory assist (NAVA) during ventilation with NAVA mode, PEEP positive pressure at the end of expiration, FIO2 fraction of inspired oxygen, P/F ratio of arterial oxygen pressure divided by the fraction of inspired oxygen on the day of the study, F continuous fentanyl, P continuous propofol, M continuous midazolam, D continuous dexmedetomidine, RASS Richmond Agitation–Sedation Scale at the day of study, NA not applicable